Transthyretin-mediated Amyloidosis
📧 Sign up to get email alerts when something new happens for Transthyretin-mediated Amyloidosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
A global observational study (ConTTRibute) of patients with transthyretin-mediated amyloidosis (ATTR amyloidosis) that is currently recruiti…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects [Phase 1]
Phase 1 trial update evaluating ALN-TTRSC04 in healthy subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamics for tr…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers [Phase 1]
Phase 1 study of Eplontersen in healthy Chinese volunteers completed to assess pharmacokinetics, pharmacodynamics, safety and tolerability.
-
CLINICAL_TRIALS trial_result · 2019-03-28Clinical Trial Update: The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant [Phase 2]
Phase 2 study evaluating Revusiran (ALN-TTRSC) in patients with TTR-mediated amyloidosis after liver transplant has completed with posted re…
-
CLINICAL_TRIALS trial_result · 2018-10-30Clinical Trial Update: The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) [Phase 2]
Phase 2 trial evaluating patisiran (ALN-TTR02) for patients with transthyretin-mediated amyloidosis who have prior exposure to the drug; stu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-09-06Clinical Trial Update: APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis [Phase 3]
Phase 3 study of patisiran (ALN-TTR02) for transthyretin-mediated amyloidosis has completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2016-02-05Clinical Trial Update: A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers [Phase 1]
Phase 1 dose-escalation study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered Revusir…
-
CLINICAL_TRIALS trial_result · 2015-05-25Clinical Trial Update: A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers [Phase 1]
Phase 1 study assessing safety, tolerability, and pharmacokinetics of ALN-TTR02 in Japanese healthy volunteers; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-15Clinical Trial Update: Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects [Phase 1]
Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of ALN-TTR02 in healthy volunteers for transthyretin-mediated amyloidosi…
-
CLINICAL_TRIALS trial_result · 2012-05-24Clinical Trial Update: Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis [Phase 1]
Phase 1 clinical trial evaluating the safety and tolerability of ALN-TTR01 in transthyretin-mediated amyloidosis has been completed.